GlassScriptPhysician profile
Elena Kruglyak
NPI 1265420020
$11,692.09
in general payments reported to CMS, 2019-2025
68 companies · $3,857 in 2025
The $3,857 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $300 · 2021: $517 · 2022: $417 · 2023: $2,634 · 2024: $3,346 · 2025: $3,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,881 · Travel and Lodging: $916 · Education: $41.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,880.73 |
| Travel and Lodging | $915.88 |
| Education | $41.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,431.01 | 2019-2025 | Darzalex, Talvey, Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $1,124.51 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| Pfizer INC. | $1,018.66 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $815.28 | 2019-2025 | Kisqali, Piqray |
| Merck Sharp & Dohme LLC | $553.46 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $508.06 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Genzyme Corporation | $466.99 | 2019-2025 | |
| Glaxosmithkline, LLC. | $400.56 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $352.80 | 2019-2025 | |
| Celgene Corporation | $348.80 | 2020-2025 | Pomalyst, Reblozyl, Opdualag |
| Array Biopharma INC | $322.27 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Incyte Corporation | $285.99 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $270.73 | 2024-2025 | Enhertu, Tagrisso, Bevespi Aerosphere |
| Eisai INC. | $253.28 | 2022-2025 | |
| Genentech USA, INC. | $249.96 | 2019-2025 | Venclexta, Tecentriq, Phesgo |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $169.14 | 2024-2025 | |
| Medtronic, INC. | $163.67 | 2025 | Synchromedii |
| Daiichi Sankyo INC. | $163.05 | 2024-2025 | Enhertu, Datroway |
| Beigene USA, INC. | $156.23 | 2023-2024 | Brukinsa, Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $153.64 | 2019-2025 | |
| Astellas Pharma US INC | $130.41 | 2023-2024 | Padcev, Xospata, Xtandi |
| Seagen INC. | $124.19 | 2023 | Adcetris, Padcev, Tivdak |
| Amgen INC. | $117.20 | 2019-2023 | Blincyto, Kyprolis |
| Pharmacosmos Therapeutics INC. | $108.00 | 2023-2025 | Monoferric |
| Alexion Pharmaceuticals, INC. | $105.28 | 2023-2025 | Ultomiris |
| Tempus Ai, INC | $102.27 | 2024-2025 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.83 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $95.20 | 2023-2025 | Fotivda |
| Adaptive Biotechnologies Corporation | $95.00 | 2023-2025 | Clonoseq |
| Mirati Therapeutics, INC. | $94.93 | 2023 | Krazati |
| Ipsen Biopharmaceuticals, INC | $94.16 | 2019-2025 | Onivyde, Somatuline Depot |
| Deciphera Pharmaceuticals INC. | $92.74 | 2025 | Qinlock, Romvimza, Tgct |
| Sumitomo Pharma America, INC. | $77.33 | 2024-2025 | Orgovyx |
| Exelixis INC. | $73.22 | 2024-2025 | Cabometyx |
| Lilly USA, LLC | $70.17 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Stemline Therapeutics INC. | $63.41 | 2023-2025 | Orserdu |
| Servier Pharmaceuticals LLC | $56.96 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $55.51 | 2023 | Imbruvica, Epkinly |
| Taiho Oncology, INC. | $44.79 | 2023-2024 | |
| Dendreon Pharmaceuticals LLC | $40.45 | 2025 | Provenge |
| Puma Biotechnology, INC. | $38.34 | 2023-2024 | |
| Myriad Genetic Laboratories, INC. | $38.26 | 2024-2025 | Myrisk |
| Adc Therapeutics America, INC. | $37.27 | 2025 | |
| Agios Pharmaceuticals, INC. | $36.55 | 2023 | Pyrukynd |
| Pharmaand Gmbh | $35.52 | 2025 | Rubraca |
| Springworks Therapeutics, INC. | $35.16 | 2024 | Ogsiveo |
| Beone Medicines USA, INC. | $34.09 | 2025 | Tevimbra |
| Tolmar, INC. | $33.39 | 2025 | Rubraca, Eligard |
| Tersera Therapeutics LLC | $32.91 | 2024 | Zoladex |
| Teva Pharmaceuticals USA, INC. | $32.12 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $30.17 | 2024 | Stimufend |
| Novocure INC. | $29.72 | 2025 | Optune Lua (Novottf-200t) |
| Shield Therapeutics INC | $28.74 | 2023 | Accrufer |
| Gilead Sciences, INC. | $26.20 | 2025 | Trodelvy |
| Blueprint Medicines Corporation | $25.07 | 2025 | Ayvakit |
| Kite Pharma, INC. | $24.16 | 2023 | Yescarta |
| Immunogen, INC. | $23.28 | 2023 | Elahere |
| Legend Biotech USA INC. | $22.90 | 2024 | |
| Kyowa Kirin, INC. | $22.68 | 2025 | |
| Rigel Pharmaceuticals, INC. | $22.37 | 2024 | Tavalisse, Rezlidhia |
| Biocon Biologics INC | $21.54 | 2024 | Ogivri |
| Regeneron Healthcare Solutions, INC. | $20.40 | 2024 | Libtayo |
| Janssen Pharmaceuticals, INC | $19.79 | 2020-2021 | |
| Myovant Sciences INC. | $18.83 | 2021 | |
| Foundation Medicine, INC. | $15.10 | 2023 | |
| Jazz Pharmaceuticals INC. | $14.86 | 2025 | |
| Tesaro, INC. | $13.41 | 2019 | |
| Secura Bio, INC. | $13.12 | 2024 | Copiktra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Kruglyak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.